

Best of ASCO® 2025 in Japan

a program licensed by the American Society of Clinical Oncology, Inc.

プログラム

※本セミナーでとりあげる演題は、2025年5月30日～6月3日に開催された米国臨床腫瘍学会（ASCO）の年次総会の演題の中から重要なものをASCOのプログラム委員会が指定し、日本臨床腫瘍学会のBest of ASCO部会が選定したものです。
但し、IDに * 印のある演題は日本臨床腫瘍学会のBest of ASCO部会が独自で選定したものです。

2025.05.26時点

7月5日（土曜日）

演題数

講師

司会

コメンテーター

9:00 – 9:1010 min

Welcome & Introduction

2 演題

9:10 – 9:3020 min

肺がん - Non-Small Cell Local-Regional/Small Cell

2 演題

9:30 – 9:4515 min

Q&A

採択演題

9:45 – 10:1530 min

肺がん - Non-Small Cell Metastatic

3 演題

10:15 – 10:3015 min

Q&A

採択演題

10:30 – 10:5020 min

脳腫瘍

2 演題

10:50 – 11:0515 min

Q&A

採択演題

11:05 – 11:3025 min

Break

採択演題

11:30 – 12:1040 min

オンコロジーライブセミナー①
ギリアド・サイエンシズ株式会社
トリプルネガティブ乳癌治療の最新情報

2 演題

12:10 – 12:155 min

Break

採択演題

12:15 – 12:3520 min

乳がん - Metastatic, TNBC and HER2+

2 演題

12:35 – 12:5015 min

Q&A

採択演題

12:50 – 13:1020 min

乳がん - Metastatic, HR+HER2-

2 演題

13:10 – 13:2515 min

Q&A

採択演題

13:25 – 13:305 min

Break

採択演題

13:30 – 14:1040 min

オンコロジーライブセミナー②
エーザイ株式会社
発売10年目を迎えたレンパチニブのこれまでとこれから

2 演題

14:10 – 14:155 min

Break

採択演題

14:15 – 14:3520 min

婦人科がん

2 演題

14:35 – 14:5015 min

Q&A

採択演題

14:50 – 15:0010 min

Geriatric Oncology

1 演題

15:00 – 15:1010 min

Q&A

採択演題

15:10 – 15:2010 min

メラノーマ／皮膚がん

1 演題

15:20 – 15:3010 min

Q&A

採択演題

15:30 – 15:355 min

Break

採択演題

15:35 – 16:1540 min

オンコロジーライブセミナー③
日本化薬株式会社
免疫チェックポイント阻害薬時代の細胞傷害性抗がん薬～シスプラチンの活かし方～

1 演題

16:15 – 16:2510 min

Highlight of the day

採択演題

Abstract ID LBA8008 / Charles M Rudin

Tarlatamab versus standard of care (SOC) chemotherapy as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis (PA) of the phase 3 DeLLphi-304 trial.

Abstract ID LBA8000 / Patrick M. Forde

Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.

Abstract ID 8506 / Tony S. K. Mok

Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.

Abstract ID LBA8505 / Shun Lu

Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.

Abstract ID 8503 / Helena Alexandra Yu

Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab.

Abstract ID 2011 / Ayal Aizer

Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial.

Abstract ID 2002 / Martin J. Van Den Bent

Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990.

Abstract ID LBA109 / Sara M. Tolaney

Sacituzumab govitecan (SG) + pembrolizumab vs chemotherapy + pembrolizumab in patients with previously untreated PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study.

Abstract ID LBA1008 / Sara M. Tolaney

Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Primary results from DESTINY-Breast09.

Abstract ID LBA4 / Nicholas C. Turner

Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.

Abstract ID LBA1000 / Erika P. Hamilton

Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)– negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.

Abstract ID LBA5500 / Sven Mahner

TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).

Abstract ID LBA5504 / Linda R. Duska

Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

Abstract ID 1505 / Ayumu Matsuoka

Geriatric assessment and management with a question prompt list using a web-based application to reduce treatment toxicity in older patients with cancer: A randomized controlled trial (J-SUPPORT 2101 study).

Abstract ID LBA9508 / Sarah Danson

Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first line treatment for metastatic melanoma: Results of the DANTE phase III trial.

Abstract ID 1506 / Erika P. Hamilton

Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.

Abstract ID LBA1009 / Sara M. Tolaney

Sacituzumab govitecan (SG) + pembrolizumab vs chemotherapy + pembrolizumab in patients with previously untreated PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study.

Abstract ID LBA1008 / Sara M. Tolaney

Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Primary results from DESTINY-Breast09.

Abstract ID LBA4 / Nicholas C. Turner

Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.

Abstract ID LBA1000 / Erika P. Hamilton

Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)– negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.

Abstract ID LBA5500 / Sven Mahner

TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).

Abstract ID LBA5504 / Linda R. Duska

Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

Abstract ID 1505 / Ayumu Matsuoka

Geriatric assessment and management with a question prompt list using a web-based application to reduce treatment toxicity in older patients with cancer: A randomized controlled trial (J-SUPPORT 2101 study).

Abstract ID LBA9508 / Sarah Danson

Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first line treatment for metastatic melanoma: Results of the DANTE phase III trial.

Abstract ID 1506 / Erika P. Hamilton

Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.

【座長】新倉 直樹 先生（東海大学）
【演者】下村 昭彦 先生（国立国際医療研究センター病院）

【座長】小野田 尚佳 先生（隈病院）
【演者】佐藤 靖祥 先生（東京大学）

【座長】上月 稔幸 先生（高知大学）
【演者】堀田 勝幸 先生（岡山大学）

Best of ASCO® 2025 in Japan

a program licensed by the American Society of Clinical Oncology, Inc.

プログラム

7月6日（日曜日）	演題数	講師	司会	コメンテーター
-----------	-----	----	----	---------

9:00	—	9:40	40 min	オンコロジーライブセミナー④ グラクソ・スミスクライン株式会社 未定		【座長】 竹中 克斗 先生（愛媛大学） 【演者】 杉本 由香 先生（三重大学）
9:40	—	9:45	5 min	Break		
9:45	—	10:05	20 min	血液がん - Lymphoma	2 演題	上田 智朗 大阪大学大学院医学系研究科
10:05	—	10:20	15 min	Q&A		南 陽介 国立がん研究センター東病院
				採択 演題		Abstract ID 7000 / Steven Wang Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial. Abstract ID 7005 / Philippe Armand WaveLINE-003: Phase 2/3 of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma
10:20	—	10:40	20 min	血液がん - Leukemia/MPN	2 演題	片桐 誠一郎 東京医科大学
10:40	—	10:55	15 min	Q&A		福島 健太郎 大阪大学大学院医学系研究科
				採択 演題		Abstract ID LBA3 / Andrew Tucker Kuykendall Results From VERIFY, a Phase 3, Double-Blind, Placebo (PBO)-Controlled Study of Rusfertide for Treatment of Polycythemia Vera (PV). Abstract ID 6506 / Eunice S. Wang Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study.
10:55	—	11:00	5 min	Break		
11:00	—	11:30	30 min	頭頸部がん	3 演題	今村 善宣 福井大学
11:30	—	11:45	15 min	Q&A		岡野 晋 国立がん研究センター東病院
				採択 演題		Abstract ID 6012 / Douglas Adkins Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. Abstract ID LBA2 / Jean Bourhis NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. Abstract ID 6007* / Susumu Okano Darolutamide plus goserelin for androgen receptor-positive salivary gland cancers: Results of phase 2 study (DISCOVERY).
11:45	—	11:55	10 min	Symptom Science and Palliative Care	1 演題	船坂 知華子 国立がん研究センター東病院
11:55	—	12:05	10 min	Q&A		片山 英樹 岡山大学病院
				採択 演題		Abstract ID 12002 / Toshimi Takano Randomized control trial to validate mitigation of chemotherapy-induced peripheral neuropathy by limb-cooling apparatus in breast cancer patients receiving paclitaxel (CECILIA)
12:05	—	12:30	25 min	Break		
12:30	—	13:10	40 min	オンコロジーライブセミナー⑤ アムジェン株式会社 SCLCの治療戦略		【座長】 岡本 勇 先生（九州大学） 【演者】 大橋 圭明 先生（岡山大学）
13:10	—	13:15	5 min	Break		
13:15	—	13:35	20 min	泌尿器がん - Prostate	2 演題	三浦 徳宣 愛媛大学大学院医学系研究科
13:35	—	13:50	15 min	Q&A		泉 浩二 金沢大学附属病院
				採択 演題		Abstract ID LBA5006 / Gerhardt Attard Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. Abstract ID 5001 / Nicholas David James Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE.
13:50	—	14:10	20 min	泌尿器がん - Non-Prostate	2 演題	前嶋 愛子 国立がん研究センター中央病院
14:10	—	14:25	15 min	Q&A		松原 伸晃 国立がん研究センター東病院
				採択 演題		Abstract ID 4500 / Michiel Simon Van Der Heijden Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial. Abstract ID 4517 / Thomas Powles Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study.
14:25	—	14:30	5 min	Break		
14:30	—	15:00	30 min	消化器がん - Gastrointestinal	3 演題	坂東 英明 国立がん研究センター東病院
15:00	—	15:15	15 min	Q&A		門脇 重憲 愛知県がんセンター
				採択 演題		Abstract ID LBA5 / Yelena Y. Janjigian Event-free survival in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). Abstract ID LBA4002 / Kohei Shitara Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.
15:15	—	15:35	20 min	消化器がん - Hepatobiliary/Pancreas	2 演題	Abstract ID LBA1 / Frank A. Sinicrope Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).
15:35	—	15:50	15 min	Q&A		丸木 雄太 国立がん研究センター中央病院
				採択 演題		Abstract ID LBA4005 / Vincent J. Picozzi PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC). Abstract ID 4008* / Thorsten Goetze Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase III AIO/CALGP/ACO-GAIN-Trial.
15:50	—	16:00	10 min	Highlight of the day		佐治 重衡 福島県立医科大学

統計学専門の先生に
逐次アドバイザーとしてQ&Aにご参加いただきます

アドバイザー

石塚 直樹

京都大学大学院医学研究科

アドバイザー

吉村 健一

名古屋市立大学